Understanding Preeclampsia: Causes, Prevention, and Treatment Options

Preeclampsia is a serious pregnancy complication that affects millions of women worldwide, posing significant risks to both mother and baby. Despite advances in medical research, it remains a leading cause of maternal and neonatal morbidity and mortality. But what exactly is preeclampsia, what causes it, and how can it be prevented or treated? In this blog, we’ll dive into the essentials of preeclampsia, explore its root causes, and discuss both pharmaceutical and complementary/alternative approaches to managing this condition.

Pregnancy can be an exciting time but also terrifying if you have concerns or a history of preeclampsia

What is Preeclampsia?

Preeclampsia is a condition that typically emerges after 20 weeks of pregnancy, characterized by high blood pressure (hypertension) and often protein in the urine (proteinuria). It affects 2-10% of pregnancies globally, with symptoms ranging from mild to severe. If left untreated, it can progress to eclampsia—marked by seizures—or other life-threatening complications like stroke, liver rupture, or kidney failure. The disorder not only jeopardizes the mother’s health but also increases the risk of preterm birth, fetal growth restriction (FGR), and long-term health issues for both mother and child, such as cardiovascular disease.

Currently, the only definitive "cure" for preeclampsia is delivery of the baby and placenta, which isn’t always ideal, especially if it occurs preterm. This reality drives ongoing research into understanding its causes and developing effective prevention and treatment strategies.

What Causes Preeclampsia?

The exact cause of preeclampsia remains elusive, earning it the nickname "disease of theories." However, experts agree that the placenta plays a pivotal role. Here’s a breakdown of the primary factors believed to contribute to its development:

1. Placental Dysfunction:

   • Impaired Placentation: Early in pregnancy, the placenta’s trophoblast cells should invade the maternal uterine spiral arteries, transforming them into wide, low-resistance vessels to ensure adequate blood flow. In preeclampsia, this process often fails, leading to placental ischemia (reduced blood flow) and hypoxia (low oxygen levels). This triggers oxidative stress and the release of harmful substances into the mother’s bloodstream.

   • Oxidative Stress and Inflammation: Studies show increased markers of oxidative damage (e.g., 8-OHdG) and inflammation in preeclamptic placentas, disrupting normal function and contributing to maternal symptoms.

   • Angiogenic Imbalance: The placenta releases excess anti-angiogenic factors like soluble fms-like tyrosine kinase-1 (sFlt-1), which binds to pro-angiogenic factors (VEGF and PlGF), impairing blood vessel growth and causing endothelial dysfunction.

2. Maternal Cardiovascular Factors:

   • Emerging research suggests that suboptimal maternal cardiovascular health—such as pre-existing hypertension or poor cardiac output—may precede and exacerbate placental issues. Conditions like chronic hypertension or congenital heart disease are strong risk factors, hinting that preeclampsia might not solely originate from the placenta but could be a cardiovascular disorder affecting placental perfusion.

3. Immune and Inflammatory Responses:

   • Dysregulation of the complement system, a part of the immune system, is implicated in preeclampsia. Excessive activation or inadequate regulation leads to inflammation and placental damage, with increased deposits of complement factors (e.g., C3, C5b-9) found in affected placentas.

   • Other immune factors, like elevated inflammatory cytokines (e.g., TNF-α, IL-6), amplify systemic inflammation, worsening maternal symptoms.

4. Genetic and Environmental Factors:

   • Genetic predispositions, such as variants in the APOL1 gene or a family history of preeclampsia, increase risk. Environmental factors like obesity, diabetes, and poor nutrition also contribute by heightening inflammation and oxidative stress.

These causes often interact in complex ways, with early-onset preeclampsia (before 34 weeks) typically linked to severe placental dysfunction and late-onset cases more tied to maternal factors. This heterogeneity complicates treatment but also opens doors to diverse prevention strategies.

Prevention and Treatment Options

Given the multifaceted nature of preeclampsia, prevention and treatment approaches range from pharmaceutical interventions to complementary/alternative therapies. Here’s a comprehensive look at both:

Pharmaceutical Interventions

1. Placental-Targeted Therapies:

   • Drugs: Repurposed medications safe in pregnancy, such as proton pump inhibitors (e.g., esomeprazole), metformin, statins (e.g., pravastatin), sulfasalazine, resveratrol, and sildenafil citrate, show preclinical promise. These drugs target placental oxidative stress, inflammation, and endothelial dysfunction. For instance, statins reduce sFlt-1 levels and improve blood flow, while metformin mitigates inflammation via NFκB inhibition.

   • Targeted Delivery: Innovative systems like nanoparticles, homing peptides, and MSC-derived exosomes aim to deliver drugs directly to the placenta, minimizing fetal exposure. Animal studies demonstrate these methods can enhance placental function and reduce symptoms.

2. Angiogenic Modulation:

   • sFlt-1 Reduction: Therapies like apheresis (using dextran sulfate columns) and small interfering RNA (siRNA) target sFlt-1 to restore angiogenic balance. Clinical trials show apheresis can prolong pregnancy by weeks, while siRNA, delivered via nanoparticles, reduces sFlt-1 in animal models, with a drug (CBP-4888) now in Phase 1 trials.

   • Peptide Therapy: Elastin-like polypeptides (ELPs) combined with VEGF counteract sFlt-1’s effects, improving maternal blood pressure in preclinical studies.

3. Complement Inhibition:

   • Eculizumab: This monoclonal antibody inhibits C5, reducing inflammation. Case reports suggest it can extend gestation in severe preeclampsia, though larger trials are needed.

   • Aspirin and Heparin: Low-dose aspirin (75-162 mg/day) is widely recommended for high-risk women before 16 weeks, reducing preeclampsia risk by up to 60% via anti-inflammatory and anticoagulant effects. Low-molecular-weight heparin (LMWH) may enhance these benefits in specific cases.

4. Vasodilators and Blood Pressure Management:

   • NO Donors: L-arginine and L-citrulline boost nitric oxide levels, improving vascular tone. Clinical trials indicate L-arginine reduces preeclampsia risk in high-risk groups.

   • Antihypertensives: Drugs like methyldopa, hydralazine, nifedipine, and labetalol manage hypertension, with additional benefits like reducing sFlt-1 (methyldopa) or inflammation (nifedipine).

5. Anti-inflammatory and Antioxidant Agents:

   • Hydroxychloroquine: Used in autoimmune conditions, it lowers preeclampsia risk by reducing inflammation, though its complement effects are less clear.

   • Statins: Beyond lipid control, they reduce inflammation and oxidative stress, with pravastatin showing promise in clinical trials for prolonging pregnancy.

6. Regenerative Therapy:

   • Mesenchymal Stem Cells (MSCs): MSC injections in animal models reduce blood pressure and inflammation, while their exosomes promote angiogenesis, offering a potential regenerative approach.

   • 
     

Complementary and Alternative Treatments

1. Nutritional Supplements:

   • Vitamin D: Deficiency (<20 ng/mL) increases preeclampsia risk fivefold, and supplementation may restore immune balance (Th1/Th2), though combined with probiotics, effects are inconsistent.

   • Vitamins C and E: Despite antioxidant potential, trials (e.g., WHO studies) show no significant prevention benefit and possible adverse effects.

   • Polyphenols: Found in chocolate, tea, and fruits, these antioxidants yield mixed results—chocolate may reduce risk, while tea might increase it due to caffeine.

2. Probiotics:

   • Gut and vaginal microbiome imbalances are linked to preeclampsia. Lactobacillus supplementation, especially late in pregnancy, may lower risk by reducing inflammation and blood pressure, though evidence is preliminary and clinical trials (e.g., NCT05554185) are ongoing.

3. Lifestyle Modifications:

   • Exercise: Pre-pregnancy physical activity reduces inflammation and improves endothelial function, potentially lowering preeclampsia risk.

   • Diet: A balanced diet rich in antioxidants and low in processed foods may mitigate oxidative stress, though specific impacts on preeclampsia are understudied.

4. Mind-Body Practices:

   • Stress reduction techniques like yoga or meditation might indirectly help by lowering blood pressure and inflammation, but direct evidence for preeclampsia prevention is lacking.
     

Challenges and Future Directions

While pharmaceutical options like aspirin and emerging therapies like siRNA show promise, their efficacy varies by timing, dosage, and patient profile. Complementary approaches, such as probiotics and vitamin D, offer gentler alternatives but lack robust evidence for widespread use. The challenge lies in personalizing treatment—preeclampsia’s causes differ between individuals, suggesting a need for tailored strategies based on specific pathways (e.g., placental vs. maternal).

Future research should focus on:

• Identifying biomarkers for early detection and personalized therapy.

• Validating novel drugs and delivery systems in larger human trials.

• Exploring integrative approaches combining pharmaceuticals with lifestyle changes.

Preeclampsia remains a complex puzzle, but with ongoing advancements, we’re moving closer to effective prevention and management, offering hope for safer pregnancies worldwide.

Disclaimer

The information provided in this blog, "Understanding Preeclampsia: Causes, Prevention, and Treatment Options," is for educational purposes only and is not intended to serve as medical advice, diagnosis, or treatment. Preeclampsia is a complex medical condition that requires professional evaluation and management by qualified healthcare providers. The content presented here summarizes current research and general knowledge as of March 27, 2025, but it does not replace personalized medical guidance. Always consult a licensed healthcare professional before making any decisions regarding your health or the health of your baby, including the use of any treatments, medications, or complementary therapies mentioned. The authors and publishers of this blog are not responsible for any actions taken based on this information.

APA References

1. Cui, J., Yang, Z., Ma, R., He, W., Tao, H., Li, Y., & Zhao, Y. (2024). Placenta-targeted treatment strategies for preeclampsia and fetal growth restriction: An opportunity and major challenge. Stem Cell Reviews and Reports, 20, 1501-1511. https://doi.org/10.1007/s12015-024-10735-1

2. de Alwis, N., Binder, N. K., Beard, S., Kaitu'u-Lino, T. J., Tong, S., Brownfoot, F., & Hannan, N. J. (2020). Novel approaches to combat preeclampsia: From new drugs to innovative delivery. Placenta, 102, 10-16. https://doi.org/10.1016/j.placenta.2020.08.022

3. Jena, M. K., Sharma, N. R., Petitt, M., Maulik, D., & Nayak, N. R. (2020). Pathogenesis of preeclampsia and therapeutic approaches targeting the placenta. Biomolecules, 10(6), 953. https://doi.org/10.3390/biom10060953

4. Kishwara, S., Ara, S., Rayhan, K. A., & Begum, M. (2009). Morphological changes of placenta in preeclampsia. Bangladesh Journal of Anatomy, 7(1), 49-54. https://doi.org/10.3329/bja.v7i1.3026

5. Melchiorre, K., Giorgione, V., & Thilaganathan, B. (2022). The placenta and preeclampsia: Villain or victim? American Journal of Obstetrics and Gynecology, 226(2, Supplement), S954-S962. https://doi.org/10.1016/j.ajog.2020.10.024

6. Myatt, L. (2002). Role of placenta in preeclampsia. Endocrine, 19(1), 103-111. https://doi.org/10.1385/ENDO:19:1:103

7. Oyston, C. J., Stanley, J. L., & Baker, P. N. (2015). Potential targets for the treatment of preeclampsia. Expert Opinion on Therapeutic Targets, 19(11), 1517-1530. https://doi.org/10.1517/14728222.2015.1088004

8. Pierik, E., Prins, J. R., van Goor, H., Dekker, G. A., Daha, M. R., Seelen, M. A. J., & Scherjon, S. A. (2020). Dysregulation of complement activation and placental dysfunction: A potential target to treat preeclampsia? Frontiers in Immunology, 10, 3098. https://doi.org/10.3389/fimmu.2019.03098

9. Roberts, J. M., & Escudero, C. (2012). The placenta in preeclampsia. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health, 2(2), 72-83. https://doi.org/10.1016/j.preghy.2012.01.001

10. Sakowicz, A., Bralewska, M., Rybak-Krzyszkowska, M., Grzesiak, M., & Pietrucha, T. (2023). New ideas for the prevention and treatment of preeclampsia and their molecular inspirations. International Journal of Molecular Sciences, 24(15), 12100. https://doi.org/10.3390/ijms241512100

11. Staff, A. C., Benton, S. J., von Dadelszen, P., Roberts, J. M., Taylor, R. N., Powers, R. W., Charnock-Jones, D. S., & Redman, C. W. G. (2013). Redefining preeclampsia using placenta-derived biomarkers. Hypertension, 61(5), 932-942. https://doi.org/10.1161/HYPERTENSIONAHA.111.00250

12. Takagi, Y., Nikaido, T., Toki, T., Kita, N., Kanai, M., Ashida, T., Ohira, S., & Konishi, I. (2004). Levels of oxidative stress and redox-related molecules in the placenta in preeclampsia and fetal growth restriction. Virchows Archiv, 444(1), 49-55. https://doi.org/10.1007/s00428-003-0922-2

13. Wu, J.-L., Jia, J., He, M.-Z., Zeng, Y., Zhang, J.-Y., Shi, E.-J., Lai, S.-Y., Zhou, X., Sharifu, L. M., & Feng, L. (2019). Placental origins of preeclampsia: Potential therapeutic targets. Current Medical Science, 39, 190-195. https://doi.org/10.1007/s11596-019-2020-2